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http:WHAT THIS PAPER ADDS
This study supplies data on the present risks for cardio- and cerebrovascular complications during infrainguinal
endovascular intervention and discusses important predictors for suffering from such complications in a pop-
ulation-based setting. Speciﬁcally, this article analyses major treatment complications in important subgroups
with peripheral arterial disease, highlighting risks during catheter-directed thrombolytic therapy.Objectives: Endovascular treatment for peripheral arterial disease (PAD) is increasingly used and also
continuously applied to more severe vascular pathology. Only few studies report on systemic complications
during these procedures, but it is important to address these risks. We report the results of a recent national
audit on cardio- and cerebrovascular complications after endovascular procedures for PAD.
Methods: Data from the Swedish Vascular Registry (Swedvasc) were retrieved on all infrainguinal endovascular
procedures performed between May 2008 and December 2011. A total of 9187 cases were analysed regarding
the prevalence of myocardial infarction and major stroke within 30 days post-intervention.
A literature review in PubMed and Cochrane databases was conducted.
Results: The risk of myocardial infarction was 0.3% in intermittent claudication, 1.2% in critical limb ischaemia
and 1% in acute limb ischaemia. Corresponding risk of major stroke was 0.4%, 0.3% and 1.4%. Thrombolytic
therapy was associated with a threefold risk of major stroke.
Only a few studies relevant to the subject were found during the literature review.
Conclusions: In this population-based study we found a low risk of cardiac complications, but catheter-
administered thrombolytic therapy entailed a non-negligible risk of major stroke.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Cardiovascular complications, Cerebrovascular complicationsPeripheral arterial disease (PAD) is a major health problem,
affecting about 18% of all individuals over the age of 60
years in Sweden.1 Patients with PAD have a high risk for
associated ischaemic heart disease2 and other manifesta-
tions of atherosclerosis. Considering the increasing life
expectancy in the western world3 and the continuous
medical improvements in cardiac disease4 and stroke5
prevention and management, it could be anticipated that
PAD would affect even more patients in the near future.responding author. J. Nordanstig, Dep. Of Vascular Surgery, Sahl-
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//dx.doi.org/10.1016/j.ejvs.2012.12.005In symptomatic PAD vascular surgical procedures are
often considered, aiming at limb-salvage or improvement of
symptoms. With the on-going and rapid developments in
endovascular techniques, a majority of these patients are
nowadays treated endovascularly.6 Endovascular treatment
offers a minimally invasive, and thereby a probably more
tolerable procedure, even in patients with high age and/or
with severe comorbidity. These techniques are continuously
applied to more severe vascular pathology, making the
procedures more complex and time-consuming; thus, there
could be a signiﬁcant risk for systemic complications even
with the use of these less invasive techniques.
There is an abundance of papers dealing with local, proce-
dure-related complications in association with endovascular
therapy.7e9 There are also many previous publications
exploring the risk for systemic (cardiac and cerebrovascular)
complications during open surgical procedures in PAD.10,11
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examine the risk of cardio- and cerebrovascular complications
in associationwith endovascular procedures for PAD.Themain
aim of this study was to assess the concurrent nationwide
prevalence of systemic complications during infrainguinal
endovascular revascularisation in Sweden and also to investi-
gate the importance of different risk factors for the treatment
outcome in routine clinical practice.
METHODS
Literature review
The PubMed and the Cochrane Clinical trials databases
were searched during a time period ranging from January
2002 to August 2012, using the following terms: ‘heart
attack’ OR ‘myocardial infarction’ OR ‘stroke’ OR ‘cerebro-
vascular accident’ OR ‘cerebrovascular event’ AND ‘Endo-
vascular’ OR ‘Atherectomy’ OR ‘Angioplasty’ OR
‘Angioplasty’, ‘balloon [MeSH]’ OR ‘stent’ OR ‘stents’ OR
‘Stenting’ OR ‘Stent graft’ OR ‘Endovascular Procedur-
es’[Mesh] AND ‘PAD’ OR ‘intermittent claudication’ OR
‘critical limb ischaemia’. The search was limited to English or
Swedish language, and excluded editorials, letters,
comments and animal studies.The Swedvasc
The National Swedish Vascular Registry (Swedvasc) is the
oldest national vascular registry in the world, collecting
prospective data from all vascular surgical procedures per-
formed in Sweden since 1994. The registry has several times
been validated regarding the accuracy of data.12e14 In 2008,
the registry was thoroughly updated (Swedvasc 2.0)6 and
the infrainguinal vascular procedures were separated in
a speciﬁc module, allowing for detailed data collection of
risk factors, performed procedures, complications and
outcomes during invasive treatment for PAD. Follow-up
visits according to the registry protocol are scheduled 1
month and 1 year after the procedure. Mortality data in
Swedvasc are retrieved by automatic cross-matching with
the Swedish National Cause of Death Registry, that contains
robust and accurate data regarding time and cause of death
for all diseased individuals in Sweden.
The deﬁnition of 30-day complications in the registry
includes all events during the procedure and under the
follow-up period of 30 days. Cerebrovascular complication is
deﬁned as major stroke (persistent neurological deﬁcit) and
cardiovascular complication as myocardial infarction.Study population
In a data set ranging from May 2008 (the launch of Swed-
vasc 2.0) to December 2011, 15,403 infrainguinal proce-
dures were registered. Of these, 9802 were endovascular
treatments and included in this study. Eighty-one per cent
of the endovascular procedures were done for chronic PAD,
13% were performed for acute limb ischaemia and 1.5%
(n ¼ 147) were done for popliteal artery aneurysms. The
procedures for popliteal artery aneurysms were excludedfrom further analysis, as were a remaining 4.9% (n ¼ 477)
because of missing data regarding the indication for surgery.
The subsequent analysed data set contained 9178 proce-
dures, of which 86% (n ¼ 7923) were for chronic limb
ischaemia and 14% (n ¼ 1255) for acute limb ischaemia.
Statistical analysis
Statistical analysis was performed using Statistical Package
for the Social Sciences (SPSS) version 20.0 (SPSS Inc., Chi-
cago, IL, USA). Categorical variables were compared using
c2 test signiﬁcance analysis. Multivariate associations were
assessed by a logistic regression analysis and the results are
presented as odds ratios (ORs). The number of predictors
used in the multivariate regression analysis was adjusted
according to the number of events, as it has been recom-
mended when using logistic or Cox regression analysis.15
Signiﬁcance was assumed at p < 0.05.Ethical considerations
Ethical approval was obtained from the Regional Ethical
Review Board at the University of Uppsala, D-nr 2012/282.
The data set from the Swedvasc was received after a formal
consent from the National Steering Committee of the
Swedvasc, according to the requirements from the registry.
RESULTS
Literature review
A total of 319 studies were found during the literature
search and the abstracts were reviewed. Only papers
reporting on either cardio- and/or cerebrovascular compli-
cations in association with endovascular procedures were
considered relevant and these are summarised in Table 1.Study population
Demographic data for the studied population are given in
Table 2. Mean age was 77  14 years in the subjects with
chronic disease, and 77  12 years in the subjects with
acute limb ischaemia. There were 52% male with chronic
disease and 54% with acute limb ischaemia. Among the
subjects with chronic disease, 24.4% (n ¼ 1937) of the
procedures were performed for intermittent claudication
and 75.5% (n ¼ 5981) for critical limb ischaemia. A total of
0.1% (n ¼ 5) lacked data regarding disease severity in
chronic disease.
In the subjects with acute limb ischaemia, according to
the TransAtlantic Inter-Society Consensus for Management
of PAD (TASC II) classiﬁcation of degree of ischaemia: 17.3%
(n ¼ 217) of the extremities were viable (TASC I), 48%
(n ¼ 603) were marginally treated (TASC IIa) and 31%
(n ¼ 388) were immediately treated (TASC IIb). A total of
3.7% (n ¼ 47) lacked data of degree of ischaemia.
Interventions
The performed endovascular procedures are given in
Table 3.
Table 1. Summary of the results of the literature review.
Year Author Type of study Participants Procedure-related
cardiovascular
complication
Procedure-related
cerebrovascular
complication
2002 Berridge DC Cochrane
review
Acute limb ischaemia,
catether-directed thrombolysis,
n ¼ 1283
Not reported 1.3%
2006 Nowygrod R Registry study PAD, lower extremity
revascularisation, n ¼ 17,193
0.86% 0.19%
2008 Kashyap
VS
Observational,
retrospective
PAD, endovascular treatment of,
extensive aortoiliac disease, n ¼ 83
1.2% Not reported
2011 Vogel TR Registry study PAD, tibioperoneal intervention,
n ¼ 13,258
3.2% Not reported
2011 Scali ST Observational,
retrospective
PAD, revascularisation of the
superﬁcial femoral artery,
n ¼ 204
Not reported 0%
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In intermittent claudication, 0.3% of the subjects developed
a myocardial infarction within 30 days after the procedure
and for critical limb ischaemia the corresponding ﬁgure was
1.2%. In acute limb ischaemia, 1% of the subjects suffered
from a myocardial infarction and this number increased to
2% for those with TASC IIb.
In the univariate analysis, the risk of myocardial infarction
within 30 days after the procedure was associated with
cardiovascular disease (p < 0.001) and diabetes (p < 0.01).
Among the subjects suffering from a myocardial infarction,
17% died within 30 days and 36% within 90 days after the
procedure.
Cerebrovascular complications
In intermittent claudication, 0.4% developed a major stroke
within 30 days after the procedure and for critical limb
ischaemia the risk was 0.3%. In acute limb ischaemia, 1.4%
of the subjects suffered from a major stroke and this
number increased to 1.6% when only subjects with acute
limb ischaemia treated with catheter-directed thrombolysis
(n ¼ 924) were analysed.
In univariate analysis, performed on the complete data set,
catheter-administered thrombolytic therapy was associatedTable 2. Demographics and risk factors in the studied population.
Chronic peripheral
arterial disease
Acute limb
ischaemia
Age (mean þ SD, years) 77  14 77  12
Gender (male/female), % 52/48 54/46
Previous or current
smoking, %
49 41
Hypertension, % 72 65
Diabetes, % 42 22
Coronary disease/
heart failure, %
39 38
Previous TIA/stroke, % 14 15
Pulmonary disease, % 12 12
Dialysis, % 5 2
S-creatinine
(mean þ SD, mmol l/l)
114  100 101  67with a signiﬁcantly increased risk for major stroke within 30
days after the procedure (p < 0.001). Among the subjects
suffering from a major stroke, 30% died within 30 days and
40% within 90 days after the procedure.Multivariate predictors of procedure-related cardio- and
cerebrovascular complications
In multivariate analysis, controlled for demographics and
other risk factors, diabetes and cardiovascular disease were
independent predictors of risk for myocardial infarction
within 30 days after the endovascular procedure (Table 4).
Thrombolytic therapy imposed a threefold increased risk of
suffering from a major stroke within 30 days (Table 5).
Adding the performed procedure (femoropopliteal vs.
crural) did not change ﬁndings.
DISCUSSION
In this large, nationwide audit of infrainguinal endovascular
procedures for PAD and acute limb ischaemia, we found
that the risk of adverse cardiac outcome within 30 days
following the procedure was generally low and associated
to the severity of the peripheral vascular disease. In thisTable 3. Actual numbers of performed endovascular procedures.
Several of the subjects received more than one of the deﬁned
interventions.
Chronic peripheral
arterial disease
(n ¼ 7923)
Acute limb
ischaemia
(n ¼ 1255)
PTA 7114 607
Subintimal angioplasty 2370 95
Stent implantation 2157 174
Stent graft implantation 325 63
Catheter-directed
thrombolysis
340 924
Percutaneous mechanical
thrombectomy
12 12
Percutaneous aspiration
thrombectomy
34 25
Other endovascular
procedures
480 142
Table 4. Multivariate analysis of the risk for myocardial infarction
within 30 days following endovascular intervention, n ¼ 9178.
p value OR 95% C.I. for EXP (B)
Lower Upper
Males .174 1.359 .873 2.116
Diabetes <0.001 2.164 1.404 3.336
s-creatinine .810 1.000 .998 1.003
Dialysis .389 1.689 .512 5.568
Pulmonary
disease
.874 1.049 .578 1.906
Cerebrovascular
disease
.979 .992 .566 1.739
Cardiac disease <0.001 2.310 1.487 3.587
Age <0.001 .958 .935 .981
J. Nordanstig et al. 273respect, we conﬁrmed previously reported cardiac risks by
Nowygrod et al.16 from 2006. Diabetes and cardiovascular
disease were independent predictors of adverse cardiac
outcome. A peri-interventional myocardial infarction
confers a high risk for subsequent death with a 90-day
mortality rate of 36%. Other authors have done similar
observations regarding the inﬂuence of a peri-procedural
myocardial infarction on long-term survival17,18 among
vascular surgery patients. However, previous reports16 have
not speciﬁcally addressed the risk of suffering from these
major complications among subjects treated for intermit-
tent claudication. A major complication risk approaching
1%, taken into account the risk of underreporting, is
a worrying ﬁnding. This is also highlighted by the fact that
not all claudicants are offered a formalised supervised
exercise program in Sweden before intervention, which
could effectively reduce the numbers at risk.
Regarding adverse cerebrovascular outcome, we found
similar risks as reported by previous authors.16 Catheter-
administered thrombolytic therapy was a signiﬁcant and
important risk factor for suffering from a major stroke
within 30 days of the procedure. There may be several
explanations for this increased stroke risk, with an OR of 3.5
(1.8e6.5). Firstly, as thrombolytics are most frequently used
for acute arterial ischaemia that may have embolic origin,
synchronous emboli to the cerebrovascular bed could be an
explanation. These intracranial emboli may be clinically
silent (or transient events unreported by the patient inTable 5. Multivariate analysis of the risk for major stroke within 30
days following endovascular intervention, n ¼ 9178. Adding more
predictors did not change ﬁndings.
p value OR 95% C.I. for EXP (B)
Lower Upper
Male gender .296 .715 .381 1.341
Diabetes .786 .914 .478 1.748
Cardiovascular
disease
.292 1.388 .754 2.554
Cerebrovascular
disease
.308 1.471 .701 3.088
Thrombolytic
therapy
<0.001 3.466 1.849 6.500
Age .322 .985 .955 1.015a situation with severe acute limb ischaemia), but with the
administration of thrombolytic drugs even a small cerebral
ischaemic lesion could be a nidus for haemorrhagic trans-
formation. This explanation is supported by the ﬁndings by
Berridge et al. (2002) who, in a large Cochrane report,19
reported a risk of haemorrhagic stroke of 1.3% when
catheter-administered thrombolytic therapy was used in the
initial management of acute limb ischaemia. However, in
our data set we cannot differentiate between ischaemic and
haemorrhagic stroke, and therefore our higher stroke rate
may partly be due to synchronous cerebral (non-haemor-
rhagic) embolic events. Another mechanism may be
dislodgement of new emboli from a cardiac origin, due to
the systemic effect during the thrombolytic infusion. This
advocates caution to use catheter-administered thrombo-
lytic therapy in cases with possible cerebral ischaemic
lesions, taken into account the risk of haemorrhagic trans-
formation. A thorough neurological clinical evaluation, and
perhaps also the use of additional brain imaging techniques
(such as diffusion-weighted magnetic resonance imaging),
could allow for accurate diagnosis of these cases before
initiating thrombolytic therapy, and thereby improving
patient selection. Both open (i.e., embolectomy) and
endovascular (i.e., percutaneous mechanical thrombectomy
and/or aspiration thrombectomy) techniques might be
preferred in cases with diagnosed synchronous cerebral
ischaemic lesions. Improvements could also be made in the
peri-interventional care during catheter-based thrombolytic
therapy. In 2010, Agle et al. reported a strong association
between haemorrhagic stroke and poor hypertension
control during the procedure.20 As for the cardiovascular
complication, the mortality rate after a cerebrovascular
complication is similarly high with 40% after 90 days.
This study has both strengths and limitations. Strength is
the prospectively collected and populations-based data,
which reﬂects concurrent clinical practise. Limitations
include the problem with registry data, with risk of data
collection inaccuracy and underreporting of cases with bad
outcomes. However, taken into account these shortcom-
ings, we think it is fair to say that the reported complication
rates in our study represent ‘at least’ the true rate, as only
major cardiac and cerebrovascular events are reported to
the registry.
In conclusion, there are quite scarce data in the literature
regarding cardio- and cerebrovascular complications in
association with endovascular procedures for PAD. In this
national audit based on Swedvasc data for infrainguinal
endovascular interventions, we found a generally low risk
for myocardial infarction and major stroke. However, the
mortality rate is high after both these peri-procedural
complications and for the subgroup with intermittent
claudication, these observed risks advocate caution with the
use of infrainguinal endovascular procedures.
Catheter-administered thrombolytic therapy imposes
a signiﬁcant risk of major stroke. A clinical implication, to
improve patient selection for thrombolytic therapy, may
include a careful pre-procedural neurological clinical eval-
uation and, if indicated, the use of appropriate brain
274 European Journal of Vascular and Endovascular Surgery Volume 45 Issue 3 March/2013imaging in selected cases. However, there is a need for
a more available and widespread access to these imaging
techniques also in the acute setting if this is to become
a reality.
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